Intraperitoneal Prophylaxis with CpG Oligodeoxynucleotides Protects Neutropenic Mice Against Intracerebral Escherichia Coli K1 Infection
Overview
Authors
Affiliations
Background: Prophylaxis with unmethylated cytosine phosphate guanidine (CpG) oligodeoxynucleotides (ODN) protects against several systemic experimental infections. Escherichia coli is a major cause of Gram-negative neonatal bacterial meningitis and also causes meningitis and meningoencephalitis in older and immunocompromised patients.
Methods: Wild-type (wt) and Toll-like receptor 9 (TLR9)-deficient mice were rendered neutropenic by intraperitoneal administration of the anti-Ly-6G monoclonal antibody. Immunocompetent and neutropenic mice received intraperitoneal CpG ODN or vehicle 72 h prior to induction of E. coli K1 meningoencephalitis.
Results: Pre-treatment with CpG ODN significantly increased survival of neutropenic wt mice from 33% to 75% (P = 0.0003) but did not protect neutropenic TLR9-/- mice. The protective effect of CpG ODN was associated with an enhanced production of interleukin (IL)-12/IL-23p40 with sustained increased levels in serum and spleen at least for 17 days after conditioning compared to buffer-treated animals. CpG-treated neutropenic wt mice showed reduced bacterial concentrations and increased recruitment of Ly6ChighCCR2+ monocytes in brain and spleen 42 h after infection. The levels of macrophage inflammatory protein 1α (MIP-1α) and interferon gamma (IFN-γ) in spleen were higher 42 h after infection in CpG-treated compared to buffer-treated neutropenic animals. In immunocompetent mice, prophylaxis with CpG ODN did not significantly increase survival compared to the buffer group (60% vs. 45%, P = 0.2).
Conclusions: These findings suggest that systemic administration of CpG ODN may help to prevent bacterial CNS infections in immunocompromised individuals.
Epigenetic Regulation of Innate and Adaptive Immune Cells in Salt-Sensitive Hypertension.
Mutchler A, Porcia Haynes A, Saleem M, Jamison S, Khan M, Ertuglu L Circ Res. 2025; 136(2):232-254.
PMID: 39819017 PMC: 11750173. DOI: 10.1161/CIRCRESAHA.124.325439.
Role of Trained Immunity in Heath and Disease.
Das S, Lavine K Curr Cardiol Rep. 2025; 27(1):18.
PMID: 39804563 DOI: 10.1007/s11886-024-02167-7.
Subhasinghe I, Ahmed K, Ayalew L, Gautam H, Popowich S, Matsuyama-Kato A Sci Rep. 2024; 14(1):18882.
PMID: 39143261 PMC: 11325023. DOI: 10.1038/s41598-024-69781-x.
Endotoxin tolerance and trained immunity: breaking down immunological memory barriers.
Lopez-Collazo E, Del Fresno C Front Immunol. 2024; 15:1393283.
PMID: 38742111 PMC: 11089161. DOI: 10.3389/fimmu.2024.1393283.
The causes and consequences of trained immunity in myeloid cells.
Bhargavi G, Subbian S Front Immunol. 2024; 15:1365127.
PMID: 38665915 PMC: 11043514. DOI: 10.3389/fimmu.2024.1365127.